Cart
sales@molnova.com
MRTX-1719
CAS No. 2630904-45-7
MRTX-1719( —— )
Catalog No. M28288 CAS No. 2630904-45-7
MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1611 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMRTX-1719
-
NoteResearch use only, not for human use.
-
Brief DescriptionMRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells.
-
DescriptionMRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
Recptor5-HT2|D2 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2630904-45-7
-
Formula Weight464.88
-
Molecular FormulaC23H18ClFN6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (215.11 mM)
-
SMILESN#CC1=C(OC2CC2)C=C(Cl)C(F)=C1C3=C(C4=CC5=C(C(NN=C5CN)=O)C=C4)C=NN3C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kjellberg B, et, al. Partial restoration by a neuroleptic (spiramide) of items of grooming behaviour suppressed by amphetamine. Arch Int Pharmacodyn Ther. 1974 Jul;210(1):61-6.
molnova catalog
related products
-
KDOAM-25
KDOAM-25 (KDM5 inhibitor KDOAM 25) is a potent, selective KDM5 sub-family(JARID1) inhibitor.
-
DDP-38003 dihydrochl...
DDP-38003 is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with IC50 of 84 nM.
-
JQKD82
JQKD82 is a selective inhibitor of KDM5 and increases H3K4me3. JQKD82 can be used in studies about the treatment of multiple myeloma.
